Drug maker Insmed (INSM) is rising 6% today after it released on Friday afternoon its estimate of the revenue generated by its Arikayce drug in 2024. The company also provided 2025 sales guidance for Arikayce and reported that it would seek to launch a new drug in the third quarter of this year. Arikayce is a treatment for a type of lung disease called Mycobacterium avium complex or MAC. The product is inhaled using a nebulizer. It was approved in 2018. A laboratory technician in a safety suit analyzing and conducting a series of experiments. Insmed's Friday Announcements The company reported that Arikayce generated about $363.7 million of sales last year, representing an increase of 19% versus 2023. That was slightly above the top of the company's guidance range. Insmed added that it expects to obtain $405 million to $425 million of revenue from the treatment in 2025. Additionally, INSM stated that it would attempt to launch its brensocatib, a drug that's supposed to treat bronchiectasis, in Q3. However, the drug has not yet been approved by the FDA, and the company indicated that it would only be able to meet its Q3 target if the agency grants the drug priority review and approves it. The drug maker is looking to launch brensocatib in the EU, UK and Japan in 2026. "We believe the upcoming clinical and commercial catalysts have the potential to redefine Insmed from a company that can serve approximately 30,000 patients today to one able to reach more than 2.5 million patients by the end of the decade," CEO Will Lewis said in a statement. While we acknowledge the potential of INSM, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。